[1]林飞燕,谢宗宙,刘英平,等.肝细胞癌肺转移患者口服索拉非尼致4级手足综合征1例并文献复习[J].中国皮肤性病学杂志,2020,(10):1176-1179.[doi:10.13735/j.cjdv.1001-7089.202002004]
 LIN Feiyan,XIE Zongzhou,LIU Yingping,et al.Hand-foot Syndrome Caused by Oral Sorafenib in A Hepatocellular Carcinoma Patient with Lung Metastases and Literature Review[J].The Chinese Journal of Dermatovenereology,2020,(10):1176-1179.[doi:10.13735/j.cjdv.1001-7089.202002004]
点击复制

肝细胞癌肺转移患者口服索拉非尼致4级手足综合征1例并文献复习()
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2020年10期
页码:
1176-1179
栏目:
病例报告
出版日期:
2020-10-01

文章信息/Info

Title:
Hand-foot Syndrome Caused by Oral Sorafenib in A Hepatocellular Carcinoma Patient with Lung Metastases and Literature Review
文章编号:
1001-7089(2020)10-1176-04
作者:
林飞燕1谢宗宙2刘英平2于伟玲2程小珍2
1.海南省第五人民医院激光美容科,海南 海口 570000; 2.海口市人民医院肿瘤化疗科,海南 海口 570208
Author(s):
LIN Feiyan1XIE Zongzhou2LIU Yingping2YU Weiling2CHENG Xiaozhen2
1.Department of Laser Cosmectomy,the Fifth People's Hospital of Hainan,Haikou 570000,China; 2.Department of Tumor Chemotherapy,Haikou People's Hospital,Haikou 570208,China
关键词:
手足综合征 索拉非尼 随访
Keywords:
Hand-foot syndrome Sorafenib Follow-up
分类号:
R 735.7; R 758.25
DOI:
10.13735/j.cjdv.1001-7089.202002004
文献标志码:
B
摘要:
患者女,59岁,在肝细胞性肝癌介入术后出现复发以及肺转移。口服索拉非尼后,出现掌跖部的红斑、水疱。患者感觉肢端麻木、肿胀伴疼痛停药后缓解,再次用药后加重,服药期间肺部检查显示病灶缩小。诊断:索拉非尼所致手足综合征。索拉菲尼片减量至200 mg,1次/d,配合维生素B6口服及凡士林软膏外用,连续用药3个月,直至肺部CT复查转移灶消失后停药。停药至今6年,未见肿瘤复发或新增转移灶。
Abstract:
A 59-year-old female presented recurrence and lung metastases after interventional treatment of hepatocellular carcinoma.After taking oral Sorafenib,there were erythema and blisters on the palms and plantars.She felt numbness and swelling with pain.The rashes and symptoms resolved after discontinuation and worsened after re-administration of the drug.During Sorafenib treatment,CT examination of the lung showed that the metastasis was reduced.Sorafenib-induced hand-foot syndrome was diagnosed.Combined with oral vitamin B6 and topical used Vaseline ointment was given.Sorafenib was reduced to 200 mg QD and was continuously used for 3 months until the lung CT reexamination showed that the metastasis was disappeared.No recurrence or metastasis was found after 6 years follow up.

参考文献/References:

[1] Velandia-Carrillo C,Wandurraga-Sánchez E,Gómez-Abreo D.Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer:a case report[J].BMC Endocr Disord,2014,14:26.
[2] 彭雪,杨文博,张寒,等.抗肿瘤药物诱导的手足综合征的诊疗进展[J].现代肿瘤医学,2019,27(8):1461-1464.
[3] Demirkan S,Gündüz Ö,Devrim T.Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol[J].JAAD Case Rep,2017,3(4):354-357.
[4] Yamamoto K,Kuzuya T,Honda T,et al.Relationship between adverse events and microbiomes in advanced hepatocellular carcinoma patients treated with sorafenib[J].Anticancer Res,2020,40(2):665-676.
[5] Jerkovich F,García Falcone MG,Pitoia F.The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer[J].Endocrine,2019,64(3):632-638.
[6] Mai H,Huang J,Zhang Y,et al.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma:a single-center clinical study[J].Oncotarget,2017,8(26):43458-43469.
[7] Mir MH,Changal KH,Aziz SA,et al.Sunitinib in metastatic renal cell carcinoma(mRCC):a developing country experience.Do our patients behave differently than the Western patients?[J].Int Urol Nephrol,2016,48(11):1811-1816.
[8] Qin C,Cao Q,Li P,et al.The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma[J].Sci Rep,2016,6:20089.
[9] 赵德华,王继生,楚明明,等.抗肿瘤药物引起手足综合征的机制及防治措施[J].中国现代应用药学,2019,36(11):1437-1442.
[10] Kamimura K,Shinagawa-Kobayashi Y,Goto R,et al.Effective prevention of sorafenib-induced hand-foot syndrome by dried-bonito broth[J].Cancer Manag Res,2018,10:805-813.
[11] 黎鹏,王炳胜,李永民.手足综合征大鼠模型血浆细胞因子的变化[J].中国皮肤性病学杂志,2017,31(1):24-26,30.
[12] Chen M,Chen J,Peng X,et al.The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome[J].Environ Toxicol Pharmacol,2017,49:81-88.
[13] Hénin E,Blanchet B,Boudou-Rouquette P,et al.Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome(HFS)[J].Cancer Chemother Pharmacol,2014,73(2):287-297.
[14] Lipworth AD,Robert C,Zhu AX.Hand-foot syndrome(hand-foot skin reaction,palmar-plantar erythrodysesthesia):focus on sorafenib and sunitinib[J].Oncology,2009,77(5):257-271.
[15] Lee SW,Lee TY,Yang SS,et al.Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib[J].JGH Open,2019,3(1):10-16.
[16] Krajewska J,Paliczka-Cieslik E,Jarzab B.Managing tyrosine kinase inhibitors side effects in thyroid cancer[J].Expert Rev Endocrinol Metab,2017,12(2):117-127.
[17] Shinagawa-Kobayashi Y,Kamimura K,Goto R,et al.Effect of histidine on sorafenib-induced vascular damage:Analysis using novel medaka fish model[J].Biochem Biophys Res Commun,2018,496(2):556-561.

备注/Memo

备注/Memo:
[基金项目] 2018年海南省卫生计生行业科研项目(18A200117)
[通信作者] 谢宗宙,E-mail:277549032@qq.com
更新日期/Last Update: 2020-10-15